

**Bevacizumab in combination with oxaliplatin and either 5-fluorouracil in combination with oxaliplatin for the treatment of metastatic colorectal cancer**

**Additional scenario analyses carried out by the ERG group for the first Committee meeting**

The additional analyses were performed in response to a request by NICE in order to be presented at the first Committee meeting that took place on 27<sup>th</sup> October 2009. These analyses were performed on 26<sup>th</sup> October 2009.

Incremental cost effectiveness ratios (ICERs) were calculated for the 2 x 2 part of the NO16966 study (XELOX and FOLFOX arms pooled, patients with prior adjuvant therapy excluded) where bevacizumab treatment duration was increased by:

- 1 month
- 2 months
- 3 months

<b>Additional bevacizumab cost</b>	<b>B-XELOX vs XELOX ICER (£)</b>	<b>B-FOLFOX-6 vs FOLFOX-6 ICER (£)</b>
1 month	<b>£47,312</b>	<b>£41,692</b>
2 months	<b>£58,270</b>	<b>£51,932</b>
3 months	<b>£69,227</b>	<b>£62,172</b>

**Note: all scenarios assume that no change in survival occurred and the treatment duration of the other components remained the same**